Histological subtypes and anatomical locations of gliomas also play a role in predicting treatment response, with low-grade gliomas harboring BRAF V600E mutations showing more favorable outcomes compared to high-grade variants.[30] Furthermore, the loss of the tumor suppressor PTEN can activate the PI3K/AKT pathway, potentially leading to resistance against BRAF and MEK inhibitors. This evidence concerns the gene BRAF and glioma.